AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxytocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| oxytocin derivatives | 2042 | 50-56-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 15 | U | N |
| 200 | U | O |
| 15 | U | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 12 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,GRK2,PDK1,PDK2,PDK4,PRKDC | 8 | |||
| kinase-selectivity-class | GRK2,PDK1 | 2 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 1.429 | Moderate | 0.66 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 17, 1980 | FDA | NOVARTIS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 904.66 | 34.70 | 405 | 6112 | 238005 | 90383925 |
| Maternal exposure during pregnancy | 706.84 | 34.70 | 391 | 6126 | 359672 | 90262258 |
| Maternal exposure during delivery | 579.77 | 34.70 | 115 | 6402 | 3731 | 90618199 |
| Postpartum haemorrhage | 511.68 | 34.70 | 96 | 6421 | 2305 | 90619625 |
| Premature delivery | 381.30 | 34.70 | 132 | 6385 | 38630 | 90583300 |
| Uterine atony | 255.22 | 34.70 | 40 | 6477 | 308 | 90621622 |
| Hypotension | 216.69 | 34.70 | 182 | 6335 | 325215 | 90296715 |
| Caesarean section | 208.82 | 34.70 | 70 | 6447 | 18507 | 90603423 |
| Drug ineffective | 194.56 | 34.70 | 350 | 6167 | 1383948 | 89237982 |
| Normal newborn | 170.95 | 34.70 | 64 | 6453 | 23298 | 90598632 |
| Uterine rupture | 158.30 | 34.70 | 32 | 6485 | 1137 | 90620793 |
| Foetal exposure during pregnancy | 154.99 | 34.70 | 71 | 6446 | 42904 | 90579026 |
| Premature baby | 124.80 | 34.70 | 52 | 6465 | 25025 | 90596905 |
| Ventilation perfusion mismatch | 121.80 | 34.70 | 23 | 6494 | 569 | 90621361 |
| Pre-eclampsia | 113.76 | 34.70 | 39 | 6478 | 11009 | 90610921 |
| Low birth weight baby | 103.67 | 34.70 | 35 | 6482 | 9432 | 90612498 |
| Anaphylactoid syndrome of pregnancy | 88.43 | 34.70 | 13 | 6504 | 61 | 90621869 |
| Electrocardiogram ST segment depression | 87.06 | 34.70 | 24 | 6493 | 3279 | 90618651 |
| Anaphylactic reaction | 79.55 | 34.70 | 59 | 6458 | 87465 | 90534465 |
| Bradycardia foetal | 79.31 | 34.70 | 16 | 6501 | 562 | 90621368 |
| Tachycardia | 74.58 | 34.70 | 73 | 6444 | 157600 | 90464330 |
| Placenta accreta | 73.09 | 34.70 | 13 | 6504 | 228 | 90621702 |
| Amniotic cavity infection | 70.37 | 34.70 | 17 | 6500 | 1379 | 90620551 |
| Uterine haemorrhage | 70.00 | 34.70 | 22 | 6495 | 4730 | 90617200 |
| Small for dates baby | 68.87 | 34.70 | 22 | 6495 | 4985 | 90616945 |
| Hypoxia | 68.47 | 34.70 | 50 | 6467 | 72349 | 90549581 |
| Failed induction of labour | 64.24 | 34.70 | 13 | 6504 | 464 | 90621466 |
| Uterine hypertonus | 63.08 | 34.70 | 12 | 6505 | 309 | 90621621 |
| Premature rupture of membranes | 62.63 | 34.70 | 21 | 6496 | 5537 | 90616393 |
| Acute pulmonary oedema | 61.95 | 34.70 | 24 | 6493 | 9556 | 90612374 |
| Foetal exposure during delivery | 61.06 | 34.70 | 12 | 6505 | 368 | 90621562 |
| Stillbirth | 60.33 | 34.70 | 22 | 6495 | 7421 | 90614509 |
| Foetal anaemia | 58.89 | 34.70 | 10 | 6507 | 132 | 90621798 |
| Disseminated intravascular coagulation | 57.57 | 34.70 | 29 | 6488 | 21509 | 90600421 |
| Endometritis | 57.35 | 34.70 | 14 | 6503 | 1186 | 90620744 |
| Uterine tachysystole | 57.24 | 34.70 | 8 | 6509 | 24 | 90621906 |
| Pulmonary oedema | 56.72 | 34.70 | 42 | 6475 | 62038 | 90559892 |
| Pericoronitis | 52.78 | 34.70 | 9 | 6508 | 122 | 90621808 |
| Maternal exposure during breast feeding | 52.71 | 34.70 | 19 | 6498 | 6201 | 90615729 |
| Fatigue | 52.24 | 34.70 | 10 | 6507 | 1154013 | 89467917 |
| Intermittent positive pressure breathing | 51.21 | 34.70 | 8 | 6509 | 60 | 90621870 |
| Retained placenta or membranes | 50.29 | 34.70 | 10 | 6507 | 326 | 90621604 |
| Delivery | 47.12 | 34.70 | 13 | 6504 | 1780 | 90620150 |
| Foetal death | 47.03 | 34.70 | 25 | 6492 | 20698 | 90601232 |
| Gestational diabetes | 46.17 | 34.70 | 20 | 6497 | 10562 | 90611368 |
| Live birth | 45.77 | 34.70 | 41 | 6476 | 79066 | 90542864 |
| Vascular resistance systemic decreased | 45.27 | 34.70 | 8 | 6509 | 135 | 90621795 |
| Hypothermia | 44.66 | 34.70 | 22 | 6495 | 15553 | 90606377 |
| Mean arterial pressure decreased | 41.90 | 34.70 | 8 | 6509 | 210 | 90621720 |
| Foetal growth restriction | 41.81 | 34.70 | 18 | 6499 | 9362 | 90612568 |
| Premature labour | 41.68 | 34.70 | 20 | 6497 | 13356 | 90608574 |
| Periventricular leukomalacia | 41.44 | 34.70 | 8 | 6509 | 223 | 90621707 |
| Vaginal haemorrhage | 39.93 | 34.70 | 26 | 6491 | 31245 | 90590685 |
| Polyhydramnios | 38.56 | 34.70 | 12 | 6505 | 2496 | 90619434 |
| Foetal heart rate deceleration abnormality | 38.01 | 34.70 | 9 | 6508 | 670 | 90621260 |
| Uterine hypotonus | 37.89 | 34.70 | 7 | 6510 | 153 | 90621777 |
| Gestational hypertension | 36.21 | 34.70 | 12 | 6505 | 3050 | 90618880 |
| Stroke volume increased | 35.53 | 34.70 | 5 | 6512 | 16 | 90621914 |
| Haemodynamic instability | 34.91 | 34.70 | 17 | 6500 | 11722 | 90610208 |
| Cardiac output increased | 34.71 | 34.70 | 8 | 6509 | 529 | 90621401 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Foetal exposure during pregnancy | 469.78 | 112.34 | 109 | 434 | 47202 | 42573590 |
| Premature baby | 230.38 | 112.34 | 54 | 489 | 23099 | 42597693 |
| Low birth weight baby | 134.95 | 112.34 | 30 | 513 | 9925 | 42610867 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 839.34 | 32.25 | 313 | 5183 | 167111 | 110416692 |
| Maternal exposure during pregnancy | 821.38 | 32.25 | 346 | 5150 | 254537 | 110329266 |
| Maternal exposure during delivery | 572.98 | 32.25 | 106 | 5390 | 3459 | 110580344 |
| Postpartum haemorrhage | 480.84 | 32.25 | 83 | 5413 | 1806 | 110581997 |
| Premature delivery | 389.39 | 32.25 | 116 | 5380 | 30516 | 110553287 |
| Uterine atony | 255.98 | 32.25 | 37 | 5459 | 235 | 110583568 |
| Caesarean section | 200.30 | 32.25 | 58 | 5438 | 13759 | 110570044 |
| Normal newborn | 190.07 | 32.25 | 62 | 5434 | 21834 | 110561969 |
| Drug ineffective | 149.00 | 32.25 | 267 | 5229 | 1520273 | 109063530 |
| Pre-eclampsia | 137.37 | 32.25 | 39 | 5457 | 8611 | 110575192 |
| Uterine rupture | 130.04 | 32.25 | 24 | 5472 | 767 | 110583036 |
| Ventilation perfusion mismatch | 123.46 | 32.25 | 23 | 5473 | 774 | 110583029 |
| Anaphylactoid syndrome of pregnancy | 94.14 | 32.25 | 13 | 5483 | 56 | 110583747 |
| Hypotension | 84.10 | 32.25 | 116 | 5380 | 523733 | 110060070 |
| Electrocardiogram ST segment depression | 83.90 | 32.25 | 24 | 5472 | 5437 | 110578366 |
| Uterine haemorrhage | 79.91 | 32.25 | 21 | 5475 | 3473 | 110580330 |
| Amniotic cavity infection | 78.02 | 32.25 | 16 | 5480 | 891 | 110582912 |
| Premature rupture of membranes | 74.03 | 32.25 | 21 | 5475 | 4616 | 110579187 |
| Tachycardia | 73.17 | 32.25 | 72 | 5424 | 226573 | 110357230 |
| Stillbirth | 71.19 | 32.25 | 20 | 5476 | 4244 | 110579559 |
| Endometritis | 65.41 | 32.25 | 14 | 5482 | 960 | 110582843 |
| Placenta accreta | 64.73 | 32.25 | 11 | 5485 | 216 | 110583587 |
| Bradycardia foetal | 63.01 | 32.25 | 10 | 5486 | 126 | 110583677 |
| Failed induction of labour | 61.20 | 32.25 | 11 | 5485 | 302 | 110583501 |
| Anaphylactic reaction | 58.15 | 32.25 | 47 | 5449 | 114253 | 110469550 |
| Acute pulmonary oedema | 57.22 | 32.25 | 24 | 5472 | 16972 | 110566831 |
| Hypoxia | 57.06 | 32.25 | 49 | 5447 | 129466 | 110454337 |
| Retained placenta or membranes | 56.38 | 32.25 | 10 | 5486 | 254 | 110583549 |
| Gestational diabetes | 56.38 | 32.25 | 19 | 5477 | 7370 | 110576433 |
| Foetal death | 55.17 | 32.25 | 23 | 5473 | 16022 | 110567781 |
| Pericoronitis | 53.81 | 32.25 | 9 | 5487 | 160 | 110583643 |
| Maternal exposure during breast feeding | 53.52 | 32.25 | 16 | 5480 | 4222 | 110579581 |
| Disseminated intravascular coagulation | 49.93 | 32.25 | 29 | 5467 | 41257 | 110542546 |
| Uterine hypertonus | 48.95 | 32.25 | 9 | 5487 | 281 | 110583522 |
| Premature labour | 48.65 | 32.25 | 18 | 5478 | 9154 | 110574649 |
| Delivery | 48.45 | 32.25 | 11 | 5485 | 990 | 110582813 |
| Vaginal haemorrhage | 48.29 | 32.25 | 24 | 5472 | 25050 | 110558753 |
| Live birth | 47.30 | 32.25 | 34 | 5462 | 69450 | 110514353 |
| Pulmonary oedema | 46.20 | 32.25 | 39 | 5457 | 100620 | 110483183 |
| Polyhydramnios | 46.04 | 32.25 | 12 | 5484 | 1921 | 110581882 |
| Vascular resistance systemic decreased | 43.26 | 32.25 | 8 | 5488 | 258 | 110583545 |
| Small for dates baby | 41.54 | 32.25 | 9 | 5487 | 653 | 110583150 |
| Uterine hypotonus | 40.88 | 32.25 | 7 | 5489 | 144 | 110583659 |
| Gestational hypertension | 39.68 | 32.25 | 11 | 5485 | 2223 | 110581580 |
| Mean arterial pressure decreased | 38.37 | 32.25 | 8 | 5488 | 483 | 110583320 |
| Stroke volume increased | 37.14 | 32.25 | 5 | 5491 | 17 | 110583786 |
| Cardiac output increased | 36.63 | 32.25 | 8 | 5488 | 603 | 110583200 |
| Hypothermia | 35.90 | 32.25 | 20 | 5476 | 26282 | 110557521 |
| Premature baby | 35.13 | 32.25 | 12 | 5484 | 4843 | 110578960 |
| Fatigue | 34.53 | 32.25 | 9 | 5487 | 1215949 | 109367854 |
| Premature separation of placenta | 33.76 | 32.25 | 9 | 5487 | 1571 | 110582232 |
| Uterine inversion | 33.40 | 32.25 | 4 | 5492 | 3 | 110583800 |
| Foetal heart rate deceleration abnormality | 33.27 | 32.25 | 6 | 5490 | 168 | 110583635 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02AC01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS UTEROTONICS Ergot alkaloids and oxytocin incl. analogues, in combination |
| ATC | H01BB02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Oxytocin and analogues |
| FDA CS | M0015703 | Oxytocin |
| FDA PE | N0000009705 | Increased Uterine Smooth Muscle Contraction or Tone |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
| FDA EPC | N0000175828 | Oxytocic |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:36063 | oxytocic |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:50779 | appetite enhancer |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:66980 | nootropic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:74518 | anti-obesity agent |
| CHEBI has role | CHEBI:176497 | geroprotector |
Related Drugs by ATC class:
G02AC Ergot alkaloids and oxytocin incl. analogues, in combination 1 drug
H01BB Oxytocin and analogues 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum hemorrhage | indication | 47821001 | |
| Incomplete miscarriage | indication | 156072005 | |
| Induction of labor | indication | 236958009 | |
| Pregnancy with abortive outcome | indication | 363681007 | |
| Placental Reserve Studies | off-label use | ||
| Multiple pregnancy | contraindication | 16356006 | |
| Grand multipara | contraindication | 18656007 | |
| Placenta previa | contraindication | 36813001 | DOID:11060 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Fetal distress | contraindication | 130955003 | |
| Deliveries by cesarean | contraindication | 200144004 | |
| Finding of malposition of fetus | contraindication | 289365005 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cats | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Cattle | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Cattle | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
| Dogs | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Dogs | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Horses | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Horses | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Sheep | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Sheep | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Uterine contractor to precipitate and accelerate normal parturition and postpartum evacuation of uterine debris | Indication |
| Swine | Postoperatively following cesarean section to facilitate involution and resistance to the large inflow of blood | Indication |
| Swine | Contracts smooth muscle cells of the mammary gland for milk letdown | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Oxytocin Injection | Zoetis Inc. | 1 |
| Oxytocin (Label Under Distributors) | Bimeda Animal Health Limited | 1 |
| Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| PVL Oxytocin Injectable | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
| Oxytocin Injection | Bimeda Animal Health Limited | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.47 | acidic |
| pKa3 | 12.94 | acidic |
| pKa4 | 13.18 | acidic |
| pKa5 | 13.47 | acidic |
| pKa6 | 13.7 | acidic |
| pKa7 | 13.89 | acidic |
| pKa8 | 6.4 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Oxytocin receptor | GPCR | AGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
| Vasopressin V1b receptor | GPCR | EC50 | 6.35 | WOMBAT-PK | |||||
| Vasopressin V2 receptor | GPCR | EC50 | 6.10 | WOMBAT-PK | |||||
| Oxytocin-neurophysin 1 | Secreted | WOMBAT-PK | |||||||
| Vasopressin V1a receptor | GPCR | EC50 | 6.91 | WOMBAT-PK | |||||
| Oxytocin receptor | GPCR | Ki | 9.05 | CHEMBL | |||||
| Vasopressin V2 receptor | GPCR | Ki | 7.21 | CHEMBL | |||||
| Vasopressin V1a receptor | GPCR | AGONIST | Ki | 6.10 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018039 | VUID |
| N0000146381 | NUI |
| D00089 | KEGG_DRUG |
| 4018039 | VANDF |
| C0030095 | UMLSCUI |
| CHEBI:7872 | CHEBI |
| CHEMBL395429 | ChEMBL_ID |
| D010121 | MESH_DESCRIPTOR_UI |
| DB00107 | DRUGBANK_ID |
| 2174 | IUPHAR_LIGAND_ID |
| 1480 | INN_ID |
| 1JQS135EYN | UNII |
| 439302 | PUBCHEM_CID |
| 7824 | RXNORM |
| 4537 | MMSL |
| 5223 | MMSL |
| d00584 | MMSL |
| 001307 | NDDF |
| 112115002 | SNOMEDCT_US |
| 12369008 | SNOMEDCT_US |
| 1JQS135EYN | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9742 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9743 | INJECTION | 10 [USPU] | INTRAMUSCULAR | ANDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6114 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6115 | INJECTION | 10 [USPU] | INTRAMUSCULAR | NDA | 20 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-116 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Pitocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-130 | INJECTION | 10 [iU] | INTRAVENOUS | NDA | 22 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-048 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-051 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-054 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-055 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 15 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-056 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-105 | INJECTION, SOLUTION | 2 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-170 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-233 | INJECTION, SOLUTION | 20 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52533-234 | INJECTION, SOLUTION | 30 [USPU] | INTRAVENOUS | unapproved drug other | 1 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-9584 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-012 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-021 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |
| Oxytocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4233 | INJECTION, SOLUTION | 10 [USPU] | INTRAVENOUS | NDA | 12 sections |